News
AKBA
1.650
+6.45%
0.100
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
Barchart · 4d ago
Weekly Report: what happened at AKBA last week (0331-0404)?
Weekly Report · 04/07 10:33
Strategic Developments and Market Opportunities Drive Buy Rating for Akebia Therapeutics
TipRanks · 04/04 10:26
Akebia Therapeutics gets EU positive recommendation for Xoanacyl
Seeking Alpha · 04/03 13:37
Akebia Therapeutics Announces Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted A Positive Opinion Recommending The European Commission To Approve Xoanacyl For Treatment Of Concomitant Elevated Serum Phosphorous And Iron Deficiency In Adult Patients With Chronic Kidney Disease
Benzinga · 04/03 12:15
Akebia announces CHMP positive opinion for XOANACYL
TipRanks · 04/03 12:12
AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROA
Reuters · 04/03 12:02
AKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHS
Reuters · 04/03 12:02
Akebia Therapeutics Initiated at Buy by Jefferies
Dow Jones · 04/01 12:14
Akebia Therapeutics Price Target Announced at $6.00/Share by Jefferies
Dow Jones · 04/01 12:14
Jefferies Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $6
Benzinga · 04/01 12:07
Akebia initiated with a Buy at Jefferies
TipRanks · 04/01 09:00
Akebia Therapeutics: Promising Growth Potential with Vafseo Leading the Charge
TipRanks · 04/01 08:35
Weekly Report: what happened at AKBA last week (0324-0328)?
Weekly Report · 03/31 10:41
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential
Barchart · 03/31 10:08
Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
TipRanks · 03/26 10:37
Weekly Report: what happened at AKBA last week (0317-0321)?
Weekly Report · 03/24 10:32
Akebia's Valuation Looks Stretched Despite Auryxia's Loss Of Exclusivity
Seeking Alpha · 03/21 13:19
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
Barchart · 03/21 13:12
Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock
NASDAQ · 03/20 22:51
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
More
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.